Trials / Unknown
UnknownNCT05106517
Denosumab vs Zoledronic Acid and Osteoporotic Compression Fracture
Attending Physician of Shenzhen People's Hospital
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 122 (estimated)
- Sponsor
- Shenzhen People's Hospital · Academic / Other
- Sex
- All
- Age
- 40 Years – 90 Years
- Healthy volunteers
- Accepted
Summary
Bone mineral density and function at 1 year after screw fixation with denosumab vs zoledronic acid for osteoporotic vertebral compression fractures: a parallel double-blind randomized controlled clinical trial
Detailed description
Conduct a single-center, double-blind, randomized controlled clinical trial according to clinical Trial Reporting Standards (CONSORT). Bone mineral density and function of osteoporotic vertebral compression fracture (OVCF) were compared 1 year after screw internal fixation with denosumab vs zoledronic acid in Shenzhen People's Hospital from September, 2021 to November, 2022. The study was approved by Shenzhen People's Hospital and informed consent was signed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Denosumab | Denosumab 60mg/6 months subcutaneously + placebo iv |
| DRUG | Zoledronic acid | Iv zoledronic acid and placebo /6 months subcutaneously |
Timeline
- Start date
- 2021-09-08
- Primary completion
- 2023-03-05
- Completion
- 2023-03-11
- First posted
- 2021-11-03
- Last updated
- 2023-02-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05106517. Inclusion in this directory is not an endorsement.